Molecular Testing Labs Validates suPAR Bio’s Systemic Chronic Inflammation Test
Share:
The Launch of a Novel Biomarker Test Measuring Systemic Chronic Inflammation
VANCOUVER, Wash. — Molecular Testing Labs (MTL) has completed validation of its Systemic Chronic Inflammation Test for quantitative measurement of soluble urokinase plasminogen activator receptor (suPAR) in human plasma in collaboration with suPAR Bio.
The Science Behind suPAR
An emerging body of research has linked suPAR levels to immune activation and chronic, low-grade inflammation.1 Researchers have proposed suPAR as a biomarker of chronic inflammation because it behaves differently from currently used standards such as CRP. suPAR responds more to sustained immune activation than to transient illness or injury, making it a comparatively stable signal of a person’s baseline inflammatory state.2 Additionally, population studies have examined lifestyle and demographic factors associated with higher suPAR levels, offering insight into how to manage systemic inflammation over time.3
Where MTL’s R&D Capabilities Come In
Validating a novel biomarker test requires assessments of key analytical performance characteristics such as accuracy, reproducibility, limit of detection, and stability to ensure reliable results before the test reaches a single patient. In addition to the analytical validation, MTL completed software and reporting development to support result reporting workflows and interpretation, as well as LIS integration.
The assay was integrated with MTL’s automated ELISA workflow, which will support consistent processing and scalability as test volumes grow. Following launch, the team has entered a structured hypercare phase focused on monitoring quality metrics and turnaround times.
A Partnership Grounded in Innovation
Working with Molecular Testing Labs has been an outstanding experience from start to finish. Their team’s professionalism and expertise are apparent at every stage of the process — from the initial sales conversations, through kickoff, implementation, and go-live.
What truly sets them apart is how well organized they are internally. The implementation process was smooth, seamless, and thorough. Transitions between their different teams were effortless, which made the entire experience feel cohesive rather than fragmented. Their combined expertise and genuine follow-through have made it easy to work with them.
The completion of this validation reflects the scientific depth and operational discipline that MTL brings to every assay we develop or validate. Bringing suPAR testing live required months of collaboration across scientific, quality, operational, and technology teams.
Highlighting Autoinflammatory Awareness Month, we are proud to support access to emerging biomarkers that help advance understanding of immune activation and inflammation while maintaining the rigorous quality standards expected in a CAP-accredited and CLIA-certified laboratory.
For further information or interview requests, please contact Media@MolecularTestingLabs.com.
Molecular Testing Labs (MTL) is a leading CAP-accredited and CLIA-certified health science and precision laboratory diagnostics company on a mission to democratize access to healthcare. By pioneering high-complexity and high-throughput diagnostic testing and decentralized lab solutions, MTL reduces barriers to care, whether it be geography, cost, stigma, and/or inconvenience. With a commitment to health equity, MTL empowers individuals and providers through innovative research and development, advanced logistics, and cutting-edge technology. MTL’s differentiated model combines scientific rigor, operational excellence, and inclusive access to help drive better health outcomes. For more information, visit MolecularTestingLabs.com or follow on LinkedIn.
suPAR Bio measures systemic chronic inflammation through a blood test for suPAR (soluble urokinase plasminogen activator receptor), a biomarker backed by over 20 years of research. Offered as a CLIA-regulated Laboratory Developed Test, the suPARbio™ test provides individuals and providers with a current inflammation level, an Age Index comparing biological to chronological age, and a trend view over repeat testing. suPAR Bio holds an exclusive U.S. distribution agreement with ViroGates A/S, the NASDAQ-listed Danish company behind suPAR’s discovery, and is headquartered in San Juan, Puerto Rico.
- Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27(3-4):157-172. pubmed.ncbi.nlm.nih.gov/19893210
- Rasmussen LJH, Petersen JEV, Eugen-Olsen J. Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation. Front Immunol. 2021;12:780641. pubmed.ncbi.nlm.nih.gov/34925360
- Haupt TH, Kallemose T, Ladelund S, Rasmussen LJH, Thorball CW, Andersen O, Pisinger C, Eugen-Olsen J. Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population. Biomark Insights. 2014;9:91-100. doi.org/10.4137/BMI.S19876
About the Author: Molecular Testing Labs
